Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.31 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15055467 | 0.84 | CYP4F2 (0.40) | CYP4F2CYP4A11USP2SMN1; SMN2TSHR | |
| SCHEMBL647828 | 0.82 | CYP4F2 (0.40) | CYP4F2CYP4A11USP2SMN1; SMN2TSHR | |
| SCHEMBL26409835 | 0.81 | SCN1A (0.36) | CYP4F2CYP4A11USP2SMN1; SMN2 | |
| SCHEMBL1772287 | 0.81 | CYP4F2 (0.39) | CYP4F2CYP4A11USP2SMN1; SMN2TSHR | |
| SCHEMBL6525370 | 0.81 | CYP4F2 (0.39) | CYP4F2CYP4A11USP2SMN1; SMN2TSHR | |
| SCHEMBL10004931 | 0.80 | MAPK1 (0.35) | CYP4F2CYP4A11USP2SMN1; SMN2 | |
| SCHEMBL1447288 | 0.79 | CYP3A4 (0.35) | USP2TSHRHSD17B10 | |
| SCHEMBL1146905 | 0.79 | CYP4F2 (0.38) | CYP4F2CYP4A11USP2SMN1; SMN2TSHR | |
| SCHEMBL28990172 | 0.78 | CYP4F2 (0.49) | CYP4F2CYP4A11USP2SMN1; SMN2TSHR | |
| SCHEMBL2780424 | 0.77 | CYP4F2 (0.36) | CYP4F2CYP4A11USP2SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1419155-B1 | PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2006-11-08 | — | — | EP | disclosed |
| US-20040198756-A1 | Medicaments | SMITHKLINE BEECHAM PLC (GB) | 2004-10-07 | — | — | US | disclosed |
| EP-1419155-A2 | PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003010138-A2 | PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198756-A1 | Medicaments | PIGO, PSAP, CD68 | CYP4F2 3762/4885CYP4A11 3816/4885USP2 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.